LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.
Publication
, Journal Article
Memmott, RM; Dennis, PA
Published in: J Clin Oncol
December 1, 2009
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
December 1, 2009
Volume
27
Issue
34
Start / End Page
e226
Location
United States
Related Subject Headings
- TOR Serine-Threonine Kinases
- Protein Serine-Threonine Kinases
- Protein Kinases
- Oncology & Carcinogenesis
- Neoadjuvant Therapy
- Metformin
- Humans
- Female
- Breast Neoplasms
- AMP-Activated Protein Kinase Kinases
Citation
APA
Chicago
ICMJE
MLA
NLM
Memmott, R. M., & Dennis, P. A. (2009). LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol, 27(34), e226. https://doi.org/10.1200/JCO.2009.25.3963
Memmott, Regan M., and Phillip A. Dennis. “LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.” J Clin Oncol 27, no. 34 (December 1, 2009): e226. https://doi.org/10.1200/JCO.2009.25.3963.
Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009 Dec 1;27(34):e226.
Memmott, Regan M., and Phillip A. Dennis. “LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.” J Clin Oncol, vol. 27, no. 34, Dec. 2009, p. e226. Pubmed, doi:10.1200/JCO.2009.25.3963.
Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009 Dec 1;27(34):e226.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
December 1, 2009
Volume
27
Issue
34
Start / End Page
e226
Location
United States
Related Subject Headings
- TOR Serine-Threonine Kinases
- Protein Serine-Threonine Kinases
- Protein Kinases
- Oncology & Carcinogenesis
- Neoadjuvant Therapy
- Metformin
- Humans
- Female
- Breast Neoplasms
- AMP-Activated Protein Kinase Kinases